{"product_id":"gsk-business-model-canvas","title":"GSK Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK's Business Model Canvas: Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine driving GSK’s success with our comprehensive Business Model Canvas. This detailed breakdown illuminates their customer segments, key resources, and revenue streams, offering a clear picture of their operational prowess.\u003c\/p\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind GSK's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003cp\u003eSee how the pieces fit together in GSK’s business model. This detailed, editable canvas highlights the company’s customer segments, key partnerships, revenue strategies, and more. Download the full version to accelerate your own business thinking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech and Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK actively engages with both smaller biotech firms and larger pharmaceutical companies. These collaborations are crucial for licensing new drug candidates, co-developing innovative treatments, and strategic acquisitions. For instance, GSK acquired IDRx in January 2025, significantly strengthening its oncology pipeline.  Furthermore, a partnership with Muna Therapeutics was established in December 2024, focusing on advancements in neurodegenerative diseases.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances grant GSK access to cutting-edge drug candidates and novel technologies. They also bring in specialized expertise that complements GSK's own robust internal research and development efforts. This synergy allows GSK to accelerate the discovery and development of new medicines, ultimately benefiting patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK actively partners with academic and research institutions to fuel its early-stage drug discovery pipeline and foster scientific advancement. These collaborations are crucial for accessing fundamental breakthroughs and cutting-edge research, particularly in complex therapeutic areas. For example, a significant collaboration with the UK Dementia Research Institute \u0026amp; HDRUK was announced in April 2025, highlighting GSK's commitment to tackling neurodegenerative diseases.\u003c\/p\u003e\n\u003cp\u003eThese partnerships often take the form of joint ventures, research grants, and data sharing agreements, all designed to accelerate the pace of innovation. By pooling resources and expertise, GSK can explore novel scientific concepts and identify promising drug candidates in fields such as oncology, immunology, and infectious diseases. In 2024, GSK's investment in external R\u0026amp;D collaborations reached substantial figures, underscoring the strategic importance of these academic ties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK leverages Contract Research Organizations (CROs) extensively to manage the complex and resource-intensive phases of drug development. These partnerships are crucial for outsourcing specialized services such as clinical trial management, data analysis, and navigating regulatory submissions across various global markets. This strategic outsourcing allows GSK to maintain agility and focus on core research while benefiting from the CROs' expertise and infrastructure, ultimately accelerating the path to market for new therapies and vaccines.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the global CRO market was valued at over $50 billion, highlighting the significant reliance of pharmaceutical giants like GSK on these external partners. By engaging CROs, GSK can efficiently scale its clinical trial operations, manage vast datasets, and ensure compliance with diverse international regulatory standards. This collaborative model is instrumental in optimizing development timelines and controlling costs associated with bringing innovative medicines and vaccines to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK’s partnerships with global health organizations and NGOs are foundational to its mission. Collaborations with entities like Save the Children are crucial for executing vital programs, such as the initiative to boost child vaccination rates in Ethiopia and Nigeria. These alliances are instrumental in navigating the complexities of vaccine distribution within developing nations and tackling broader global health crises.\u003c\/p\u003e\n\u003cp\u003eThese partnerships frequently involve sophisticated arrangements like tiered pricing structures and supply agreements. They also extend to joint initiatives designed to ensure that life-saving medicines and vaccines are accessible to populations worldwide, promoting health equity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSave the Children Partnership:\u003c\/strong\u003e GSK’s commitment with Save the Children focuses on increasing childhood vaccination coverage in regions like Ethiopia and Nigeria, directly impacting public health outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEquitable Access:\u003c\/strong\u003e Through these collaborations, GSK aims to provide affordable and accessible healthcare solutions, leveraging tiered pricing and supply chain innovations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Health Impact:\u003c\/strong\u003e These alliances are critical for addressing significant global health challenges, particularly in low- and middle-income countries where access to essential medicines can be limited.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply Chain Optimization:\u003c\/strong\u003e Working with NGOs helps GSK to optimize its supply chains for efficient and effective delivery of vaccines and medicines to remote and underserved communities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernments and Public Health Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK actively collaborates with governments and public health bodies worldwide. This engagement is vital for securing large-scale procurement contracts for its vaccines and essential medicines, which is a cornerstone of its revenue generation. For instance, in 2024, GSK continued its significant partnerships with national health ministries for the supply of its influenza vaccines, contributing to public health preparedness during seasonal outbreaks. These partnerships also enable GSK to participate in and support crucial public health campaigns aimed at disease prevention and health education, thereby enhancing product demand and brand trust.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances are instrumental in integrating GSK's innovative treatments and preventive solutions into national healthcare systems and public health programs. This integration ensures broader patient access and facilitates the widespread availability of GSK's portfolio, directly impacting its market penetration and sales volumes. For example, ongoing discussions in 2024 with several European Union member states focused on expanding access to GSK's respiratory syncytial virus (RSV) vaccine for older adults, a key growth area. Furthermore, by influencing healthcare policy, GSK can shape the future landscape for its products, ensuring alignment with public health priorities and fostering long-term growth opportunities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eVaccine Procurement:\u003c\/strong\u003e Governments are major purchasers of GSK's vaccines, such as those for influenza and shingles, driving significant revenue. In 2024, GSK secured substantial orders for its Shingrix vaccine from national immunization programs in North America and Europe.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePublic Health Campaigns:\u003c\/strong\u003e Partnerships support disease awareness and prevention initiatives, boosting the uptake of GSK's products. For example, collaborations in 2024 focused on increasing childhood immunization rates and promoting awareness around respiratory illnesses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy Shaping:\u003c\/strong\u003e Engagement with health ministries influences healthcare policy, benefiting GSK's market access and product integration. Discussions in 2024 aimed at favorable reimbursement policies for new biologic therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Alignment:\u003c\/strong\u003e Working with public health bodies ensures GSK's products meet national regulatory standards and public health needs, facilitating market entry and sustained sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Drug Innovation and Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK's key partnerships with other pharmaceutical and biotech companies are vital for acquiring new drug candidates and sharing development risks. These collaborations allow GSK to access novel technologies and expand its therapeutic reach, particularly in areas like oncology and immunology. For example, in 2024, GSK entered into a strategic alliance with a leading AI-driven drug discovery firm, enhancing its early-stage research capabilities.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA strategic framework detailing GSK's approach to developing, manufacturing, and distributing innovative medicines and vaccines, focusing on patient needs and global health challenges.\u003c\/p\u003e\n\u003cp\u003eThis model outlines GSK's key partnerships, R\u0026amp;D activities, and cost structures to deliver value propositions across diverse customer segments, including patients, healthcare providers, and governments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe GSK Business Model Canvas acts as a pain point reliever by providing a structured, visual framework to pinpoint and address inefficiencies within their complex pharmaceutical operations.\u003c\/p\u003e\n\u003cp\u003eIt simplifies the identification of resource gaps and strategic misalignments, offering a clear path to optimizing R\u0026amp;D, manufacturing, and distribution processes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK's central activity is robust scientific research, focusing on discovering new drug targets and creating innovative compounds. This deep scientific exploration is the engine driving their pipeline.  In 2024, GSK committed a substantial £6.4 billion to its R\u0026amp;D efforts, underscoring the scale of this crucial operation.\u003c\/p\u003e\n\u003cp\u003eThe company strategically directs its R\u0026amp;D into four key therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. This focused approach allows for concentrated expertise and resource allocation.\u003c\/p\u003e\n\u003cp\u003eThis concentrated R\u0026amp;D strategy aims to bring a significant number of new treatments to market, with GSK targeting the launch of 14 new medicines and vaccines between 2025 and 2031. This ambitious goal highlights the company's commitment to innovation and addressing unmet medical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Global Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing high-quality vaccines and specialty medicines at scale is a core activity for GSK, demanding intricate production processes and stringent quality assurance. This commitment is underscored by substantial investments, including £200 million allocated to UK manufacturing facilities between 2023 and 2025, and a significant up to $800 million investment in a US site planned for 2024.\u003c\/p\u003e\n\u003cp\u003eEfficient global supply chain management is crucial for ensuring these vital products reach patients worldwide safely and reliably. GSK leverages advanced technologies, such as digital twins and robotics, to optimize logistics and maintain product integrity throughout the distribution network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesigning, executing, and meticulously monitoring large-scale clinical trials are foundational activities for GSK, essential for substantiating the efficacy and safety of new pharmaceutical products. This rigorous process involves thousands of participants and significant investment to gather robust data.\u003c\/p\u003e\n\u003cp\u003eNavigating the complex and ever-evolving global regulatory approval processes, such as those managed by the FDA and EMA, is equally critical. GSK's strategic focus includes securing timely approvals for its innovative pipeline, aiming for five major new FDA product approvals in 2025, including anticipated launches for Penmenvy and Blujepa.\u003c\/p\u003e\n\u003cp\u003eThese activities are not merely procedural; they are the gateway to market access, ensuring that GSK's treatments meet stringent compliance standards set by health authorities worldwide. Successful navigation of this pathway allows GSK to bring life-changing and life-saving medicines to patients efficiently and responsibly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGSK's sales, marketing, and distribution efforts are crucial for ensuring their innovative healthcare solutions reach patients. This involves actively promoting products to healthcare professionals and institutions, highlighting the benefits of their medicines and vaccines. In 2023, GSK continued to invest heavily in its commercial infrastructure to support its diverse portfolio.\u003c\/p\u003e\n\u003cp\u003eEffectively managing extensive global distribution networks is another key activity. This ensures timely and secure access to GSK's products across numerous markets. Their supply chain operations are designed to meet the complex demands of pharmaceutical and vaccine delivery worldwide.\u003c\/p\u003e\n\u003cp\u003eEngaging with patient advocacy groups is also a vital component. These partnerships help GSK understand patient needs better and communicate the value of their treatments. This collaborative approach fosters trust and supports patient access to necessary medical interventions.\u003c\/p\u003e\n\u003cp\u003eThese core activities are underpinned by a robust global commercial presence, allowing GSK to navigate diverse regulatory environments and market dynamics. For instance, GSK's respiratory franchise, which includes products like Trelegy Ellipta, saw significant growth in recent periods, demonstrating the effectiveness of their commercial strategies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoting to Healthcare Professionals\u003c\/strong\u003e: GSK employs a dedicated sales force and utilizes digital channels to educate physicians and hospital administrators about their pharmaceutical and vaccine offerings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManaging Distribution Networks\u003c\/strong\u003e: The company operates a complex global supply chain, ensuring its products are available in pharmacies, hospitals, and clinics worldwide, adhering to strict temperature and handling requirements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngaging Patient Advocacy Groups\u003c\/strong\u003e: GSK collaborates with patient organizations to raise disease awareness, improve access to treatment, and gather valuable patient insights.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Commercial Presence\u003c\/strong\u003e: In 2023, GSK maintained a presence in over 100 countries, adapting its marketing and distribution strategies to local market needs and healthcare systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGSK's intellectual property management is crucial for safeguarding its innovations, particularly its vast patent portfolio. This involves actively defending patents against infringement and strategically expanding them to cover new therapeutic areas or formulations. For example, in 2024, GSK continued to leverage its strong patent position for key products like Trelegy Ellipta, a respiratory treatment, ensuring continued market exclusivity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Defense:\u003c\/strong\u003e GSK employs robust legal strategies to protect its patented medicines and vaccines from generic competition, ensuring return on its substantial research and development investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrademark Protection:\u003c\/strong\u003e The company actively manages and protects its brand names and trademarks, which are vital for consumer recognition and trust in its pharmaceutical and vaccine offerings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Expansion:\u003c\/strong\u003e GSK continuously seeks to strengthen its proprietary portfolio by filing new patents for product improvements, new indications, and novel drug delivery systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment Safeguard:\u003c\/strong\u003e Intellectual property protection is fundamental to GSK's business model, directly enabling it to recoup the billions invested annually in discovering and developing new treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Lab to Patient: Global Medicine \u0026amp; Vaccine Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK's key activities revolve around discovery and development of new medicines and vaccines, manufacturing these at scale, and ensuring their global distribution. This includes rigorous clinical trials and navigating complex regulatory pathways to bring innovative treatments to patients worldwide.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe GSK Business Model Canvas you are previewing is the actual document you will receive upon purchase. This isn't a sample or a mockup; it's a direct representation of the complete, ready-to-use file. Once your order is processed, you'll gain full access to this professionally structured Business Model Canvas, allowing you to immediately begin refining GSK's strategic framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480529813881,"sku":"gsk-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gsk-business-model-canvas.png?v=1752754890","url":"https:\/\/growthsharematrix.com\/products\/gsk-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}